In support of this, patients with high RPSAP52 expression levels had poorer prognosis than cases with low expression in the sarcoma patients cohort from TCGA database, whereas HMGA2 expression did not show any prognostic effect in the same cohort (Fig. 7c). Here, RPSAP52 is linked to sarcoma.